Trials / Completed
CompletedNCT00121680
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7080 | Oral. |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2011-09-01
- Completion
- 2015-05-01
- First posted
- 2005-07-21
- Last updated
- 2015-12-11
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00121680. Inclusion in this directory is not an endorsement.